Generalised convulsive status epilepticus: An overview

Postgraduate Medical Journal

Volumn 82, Issue 973, 2006, Pages 723-732

  Nandhagopal, R ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; HUMAN; METHODOLOGY; PROGNOSIS; RECURRENT DISEASE; REVIEW;

ANTICONVULSANTS; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; HUMANS; PROGNOSIS; RECURRENCE; STATUS EPILEPTICUS;

EID: 39049195564     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2005.043182     Document Type: Review

References (91)

1. Shorvon SD. The management of status epilepticus. J Neurol Neurosurg Psychiatry 2001;70:1122-7.
2. Meena AK, Prasad VS, Kaul S, et al. Neurological intensive care in India-disease spectrum and outcome. Neurol India 2000;48:S1-7.
3. Pellock JM. Management of acute seizure episodes. Epilepsia 1998;39:S28-35.
4. Dodson WE, DeLorenzo RJ, Pedley TA, et al. The treatment of convulsive status epilepticus: recommendations of Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993;270:854- 9.
5. Bleck TP. Convulsive disorders: status epilepticus. Clin Neuropharmacol 1991;14:191-8.
6. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-8.
7. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345:631-7.
8. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999;40:120-2.
9. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors and impact on outcome. Arch Neurol 2002;59:205-10.
10. Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonic- clonic seizure: a videotape analysis. Neurology 1994;44:1403-7.
11. DeGiorgio CM, Heck CN, Rabinowicz AL, et al. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 1999;52:746-9.
12. Rice AC, DeLorenzo RJ. N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. Neuroscience 1999;93:117-23.
13. Holtkamp M, Othman J, Buchheim K, et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005;76:534-9.
14. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:1698-702.
15. Holtkamp M, Othman J, Buchheim K, et al. A "malignant" variant of status epilepticus. Arch Neurol 2005;62:1428-31.
16. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39:833-40.
17. Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003;74:189-91.
18. Kaplan PW. Nonconvulsive status epilepticus in the emergency room. Epilepsia 1996;37:643-50.
19. Walker MC, Howard RS, Smith SJ, et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q J Med 1996;89:913-20.
20. Cragar DE, Berry DT, Fakhoury TA, et al. A review of diagnostic techniques in the differential diagnosis of epileptic and nonepileptic seizures. Neuropsychol Rev 2002;12:31-64.
21. Leis AA, Ross MA, Summers AK. Psychogenic seizures:ictal characteristics and diagnostic pitfalls. Neurology1992;42:95-9.
22. Chen DK, So YT, Fisher RS. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2005; 65:668-75.
23. Tomson T, Lindbom U, Nilsson BY, et al. Serum prolactin during status epilepticus. J Neurol Neurosurg Psychiatry1989;52: 1435-7.
24. Noe KH, Manno EM. Mechanisms underlying status epilepticus. Drugs Today (Barc) 2005;41 :257-66.
25. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005;25:7724-33.
26. Goodkin HP, Yeh JL, Kapur J. Status epilept icus increases the intracellular accumulation of GABAA receptors. J Neurosci 2005;25:5511-20.
27. Macdonald RL, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia 1999;40:S9-20.
28. Kapur J. Status epilepticus in epileptogenesis. Curr Opin Neurol 1999;12:191-5.
29. Rafiq A, Gong QZ, Lyeth BG, et al. Induction of prolonged electrographic seizures in vitro has a defined threshold and is all or none: implications for diagnosis of status epilepticus. Epilepsia 2003;44:1034-41.
30. Fujikawa DG. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav 2005;7:3-11.
31. Niquet J, Liu H, Wasterlain CG. Programmed neuronal necrosis and status epilepticus. Epilepsia 2005;46:43-8.
32. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective population based epidemiological study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029-35.
33. Shorvon S, Walker M. Status epilepticus in idiopathic generalized epilepsy. Epilepsia 2005;46:73-9.
34. Delanty N, French JA, Labar DR, et al. Status epilepticus arising de novo in hospitalized patients: an ana lysis of 41 patients. Seizure 2001;10:116-19.
35. Velioglu SK, Ozmenoglu M, Boz C, et al. Status epilepticus after stroke. Stroke 2001;32:1169-72.
36. Lee KC, Garcia PA, Alldredge BK. Clinical features of status epilepticus in patients with HIV infection. Neurology2005;65:314- 16.
37. Hillbom M, Pieninkeroinen I, Leone M. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs 2003;17:1013-30.
38. Claassen J, Mayer SA. Continuous electroencephalographic monitoring in neurocritical care. Curr Neurol Neurosci Rep 2002;2:534-40.
39. Treiman D, Walton N, Kendrick C. A progressive sequence of electroencephalographic changes during generalised convulsive status epilepticus. EpilepsyRes 1990;5:49-60.
40. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 1999;40:759-62.
41. Roppolo LP, Walters K. Airway management in neurological emergencies. Neurocrit Care 2004;1 :405-14.
42. Huang CC, Chen TW, Lin FC, et al. Status epilepticus as an initial presentation of Brugada syndrome: a case report. Kaohsiung JMedSci 2005;21 :387-91.
43. Boggs JG, Painter JA, DeLorenzo RJ. Analysis of electrocardiographic changes in status epilepticus. EpilepsyRes 1993;14:87-94.
44. Manno EM, Pfeifer EA, Cascino GD, et al. Cardiac pathology in status epilepticus. Ann Neurol 2005;58:954-7.
45. Appleton R, SweeneyA, Choonara I, et al. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995;37:682-8.
46. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452-4.
47. Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989;30:S4-10.
48. Pang T, Hirsch LJ. Treatment of convulsive and nonconvulsive status epilepticus. Curr Treat Options Neurol 2005;7:247-59.
49. Walker M. Status epilepticus: an evidence based guide. BMJ 2005;331 :673-7.
50. Prasad K, Al-Roomi K, Krishnan P, et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2005;4:CD003723.
51. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005;366:205-10.
52. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999;353:623-6.
53. Towne AR, DeLorenzo R. Use of intramuscular midazolam for status epilepticus. J Emerg Med 1999;17:323-8.
54. Jeannet PY, Roulet E, Maeder-Ingvar M, et al. Home and hospital treatment of acute seizures in children with nasal midazolam. Eur J Pediatr Neurol 1999;3:73-7.
55. Scheepers M, Scheepers B, Clarke M, et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure 2000;9:417-22.
56. Body R, Ijaz M. Buccal midazolam as an alternative to rectal diazepam for prolonged seizures in childhood and adolescence. Emerg Med J 2005;22:364-5.
57. Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res 2002;24:842-8.
58. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia 2001;42:1156-9.
59. Rudis MI, Touchette DR, Swadron SP, et al. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med 2004;43:386-97.
60. Swadron SP, Rudis MI, Azi mian K, et al. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med 2004;11 :244-52.
61. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology1996;46:S3-7.
62. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol 2005;28:243-4.
63. Pandey CK, Singh N, Bose N, et al. Gabapenti n and propofol for treatment of status epilepticus in acute intermittent porphyria. J Postgrad Med 2003;49:285.
64. Holstege CP, Dob meier SG. Nerve agent toxicity and treatment. Curr Treat Options Neurol 2005;7:91-8.
65. Beydoun A, Vanderzant C, Kutluay E, et al. Full neurologic recovery after fulminant thrombotic thrombocytopenic purpura with status epilepticus. Seizure 2004;13:549-52.
66. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulphate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;33:201-5.
67. Holtkamp M, Masuhr F, H arms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neuro logists. J Neurol Neurosurg Psychiatry2003;74:1095-9.
68. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 2003;211 :37-41.
69. Walker MC, Smith SJ, Shorvon SD. The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations. Anaesthesia 1995;50:130-5.
70. Prasad A, Worrall BB, Bertram EH, et al. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001;42:380-6.
71. Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004;45:757-63.
72. Claassen J, Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-53.
73. Labar DR, Ali A, Root J. High dose intravenous lorazepam for the treatment of refractory status epilepticus. Neurology1994;44:1400- 3.
74. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004;61 :1254-9.
75. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46:967-9.
76. Patwardhan RV, Dellab adia J Jr, Rashidi M, et al. Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report. Surg Neurol 2005;64:170-3.
77. Duane DC, Ng YT, Rekate HL, et al. Treatment of refractory status epilepticus with hemispherectomy. Epilepsia 2004;45:1001-4.
78. Ma X, Liporace J, O'Connor MJ, et al. Neurosurgical treatment of medically intractable status epilepticus. Epilepsy Res 2001;46:33-8.
79. Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005;64:353-5.
80. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus-experience in 102 adult patients. Seizure 2005;14:164-9.
81. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001 ;35:1465-70.
82. Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35:147-53.
83. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology2003;60:332- 4.
84. Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav 2003;4:757-60.
85. Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005;54:34-8.
86. DeGiorgio CM, Tomiyasu U, Gott PS, et al. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia 1992;33:23-7.
87. Howard RS, Radcliffe J, Hirsch NP. General medical care on the neuromedical intensive care unit. J Neurol Neurosurg Psychiatry 2003;74:10-15.
88. DeLorenzo RJ, Towne AR, Pellock JM, et al. Status epilepticus in children, adults and the elderly. Epilepsia 1992;33:515-25.
89. Towne A, Pellock J, Ko D, et al. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27-34.
90. Scholtes FB, Renier WO, Meinardi H. Generalised convulsive status epilepticus: causes, therapy and outcome in 346 patients. Epilepsia 1994;35:1104-12.
91. Cascino GD, Hesdorffer D, Logroscino G, et al. Morbidity of nonfebrile status epilepticus in Rochester, Minnesota, 1965-1984. Epilepsia 1998;39:829-34.